S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung

• Main Authors: Mengyao Hao (Author), Rong Fu (Author), Jun Tai (Author), Zhenhuan Tian (Author), Xia Yuan (Author), Yang Chen (Author), Mingjin Wang (Author), Huimin Jiang (Author), Ming Ji (Author), Fangfang Lai (Author), Nina Xue (Author), Liping Bai (Author), Yizhun Zhu (Author), Xiaoxi Lv (Author), Xiaoguang Chen (Author), Jing Jin (Author)
• Format: Book
• Published: Elsevier, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology and limited treatment options. The median survival time for IPF patients is approximately 2-3 years and there is no effective intervention to treat IPF other than lung transplantation. As important components of...